• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Mild Cognitive Impairment Market

    ID: MRFR/HC/9432-CR
    151 Pages
    Rahul Gotadki
    May 2024

    Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson’s Disease Dementia, Alzheimer’s Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Mild Cognitive Impairment Market Infographic
    Purchase Options

    Mild Cognitive Impairment Market Summary

    As per Market Research Future Analysis, the Global Mild Cognitive Impairment Market was valued at USD 2.05 Billion in 2024 and is projected to grow to USD 3.87 Billion by 2035, with a CAGR of 5.95% from 2025 to 2035. The growth is driven by the increasing prevalence of mild cognitive impairment (MCI) and rising awareness. However, challenges such as polypharmacy and managing comorbidities may hinder market growth. Technological advancements for early diagnosis present lucrative opportunities.

    Key Market Trends & Highlights

    The increasing burden of mild cognitive impairment globally fuels market growth.

    • Approximately 8 million Americans suffer from mild cognitive impairment as of October 2023.
    • Over 10 million Europeans are reported to have MCI as of January 2024.
    • 12% to 18% of individuals aged 60 or older in America are living with MCI.
    • The geriatric population is growing faster than younger demographics, increasing MCI cases.

    Market Size & Forecast

    2024 Market Size USD 2.05 Billion
    2035 Market Size USD 3.87 Billion
    CAGR (2024-2035) 5.95%

    Major Players

    Key players include Johnson & Johnson Services, Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Biogen, Eisai Co., Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited.

    Mild Cognitive Impairment Market Trends

    Increasing burden of mild cognitive impairment across the globe fuels market growth

    The increasing prevalence of mild cognitive impairment (MCI) globally is serving as a significant catalyst for the expansion of the global MCI treatment market. For instance, in October 2023, the University of Southern California (US) reported that approximately eight million Americans are suffering from mild cognitive impairment. Furthermore, in January 2024, CORDIS revealed that more than 10 million Europeans show MCI. Also, in March 2022, Karolinska Institute stated that more than one fourth of the older population in rural China was affected by MCI. Moreover, one of the major factors contributing to mild cognitive impairment is the growing geriatric population.

    As per the Alzheimer’s Association 2022 report, nearly 12% to 18% of people aged 60 or older are living with MCI in America. According to the World Population Prospects 2022, the population over the age of 65 is growing faster than the population under that age. Hence, the increasing MCI cases contributed to the increase in the burden of MCI, boosting the demand for treatment interventions across the globe and thus burgeoning the Mild Cognitive Impairment Market.

    The increasing prevalence of Mild Cognitive Impairment among aging populations necessitates a multifaceted approach to diagnosis and intervention, highlighting the urgent need for enhanced healthcare strategies.

    National Institute on Aging

    Mild Cognitive Impairment Market Drivers

    Market Growth Projections

    Advancements in Diagnostic Technologies

    Technological advancements in diagnostic tools are significantly influencing the Global Mild Cognitive Impairment Market Industry. Innovations such as neuroimaging techniques and biomarker identification enable healthcare professionals to detect mild cognitive impairment more accurately and earlier than before. These advancements not only enhance diagnostic precision but also facilitate timely interventions, which are crucial for improving patient outcomes. As the market evolves, the integration of artificial intelligence in diagnostic processes may further streamline assessments, potentially increasing the market's value to 3.87 USD Billion by 2035. This trend underscores the importance of technological integration in addressing cognitive health challenges.

    Enhanced Support Services and Care Models

    The Global Mild Cognitive Impairment Market Industry is also shaped by the development of enhanced support services and care models tailored for individuals with cognitive impairments. These services include specialized care facilities, community-based programs, and telehealth solutions that provide accessible support to patients and their families. The integration of holistic approaches to care, which encompass physical, emotional, and social well-being, is becoming increasingly important. As these services evolve, they are likely to attract more individuals seeking assistance, thereby contributing to the market's growth trajectory. This trend emphasizes the need for comprehensive care solutions in addressing the complexities of mild cognitive impairment.

    Rising Awareness and Education Initiatives

    The Global Mild Cognitive Impairment Market Industry is benefiting from rising awareness and education initiatives aimed at both healthcare professionals and the general public. Campaigns designed to educate individuals about the signs and symptoms of mild cognitive impairment are crucial for early detection and intervention. Increased awareness leads to higher rates of diagnosis and treatment, which in turn drives market growth. Furthermore, educational programs targeting caregivers and families play a vital role in supporting those affected by cognitive impairment. As awareness continues to grow, the market is poised to expand, reflecting a collective effort to address cognitive health challenges.

    Increasing Prevalence of Cognitive Disorders

    The Global Mild Cognitive Impairment Market Industry is experiencing growth due to the rising prevalence of cognitive disorders among the aging population. As individuals age, the risk of developing mild cognitive impairment increases, with estimates suggesting that approximately 15 to 20 percent of older adults may experience this condition. This demographic shift is projected to drive the market value to 2.05 USD Billion in 2024, highlighting the urgent need for effective interventions and support systems. The increasing awareness of cognitive health and the importance of early diagnosis further contribute to the demand for services and products within this market.

    Growing Investment in Research and Development

    Investment in research and development is a key driver for the Global Mild Cognitive Impairment Market Industry. Governments and private organizations are increasingly funding studies aimed at understanding the underlying mechanisms of mild cognitive impairment and exploring new therapeutic options. This focus on research is expected to yield innovative treatments and preventive measures, thereby expanding the market. The anticipated compound annual growth rate (CAGR) of 5.93% from 2025 to 2035 reflects the growing recognition of the need for effective solutions in cognitive health. Such investments are likely to enhance the overall landscape of the market, fostering advancements that could benefit millions.

    Market Segment Insights

    Mild Cognitive Impairment Market Disease Type Insights

    The Mild Cognitive Impairment Market segmentation, based on disease type, amnestic MCI and non-amnestic MCI. The amnestic MCI segment dominated the market in 2022 and is projected to be the fastest-growing during the forecast period, 2023–2032. Amnestic Mild Cognitive Impairment (MCI) is a subtype of MCI characterized by memory deficits beyond what is expected for a person's age but not severe enough to meet the criteria for dementia.

    Individuals with amnestic MCI typically exhibit memory impairment that is greater than expected for their age and educational level but do not show significant impairments in other cognitive domains such as language, executive function, or visuospatial skills. Amnestic MCI is considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease. Research suggests that individuals with amnestic MCI have an increased risk of progressing to Alzheimer's disease or other forms of dementia compared to those without cognitive impairment.

    Figure 2: Mild Cognitive Impairment Market, by Disease Type, 2023 & 2032 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Mild Cognitive Impairment Market Age Insights

    The mild cognitive impairment market segmentation, based on age, includes child, adult, and geriatric. The geriatric segment dominated the market in 2022 and adult is projected to be the fastest-growing during the forecast period, 2023–2032. Mild cognitive impairment (MCI) in geriatric individuals, particularly those aged 65 and older, is a common concern in clinical settings. For instance, Globally, the prevalence of cognitive impairment in individuals aged 50 years or older ranges from 5.1 to 41.0%, with a median of 19.0%. In children, mild cognitive impairment may manifest as difficulties in learning, memory, attention, executive functions, or language skills.

    Some potential causes include genetic factors, prenatal exposure to toxins or infections, perinatal complications, traumatic brain injury, neurodevelopmental disorders like autism spectrum disorder or attention deficit hyperactivity disorder (ADHD), and certain medical conditions affecting brain development.

    Mild Cognitive Impairment Market Indication Insights

    The Mild Cognitive Impairment Market has been segmented, based on indication into Lewy body dementia, Parkinson’s disease dementia, Alzheimer’s disease, vascular dementia, and others. The Alzheimer’s disease segment dominated the market in 2022 and Parkinson’s disease dementia is projected to be the fastest-growing during the forecast period, 2023–2032. Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects memory, cognition, and behavior. It is the most common cause of dementia among older adults. For instance, more than 6 million Americans of all ages suffer with Alzheimer's disease.

    In 2023, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer's. Seventy-three percent are aged 75 or older. Alzheimer's affects around one in every nine adults aged 65 and older (10.7%). Alzheimer's disease typically begins with subtle memory loss and progresses to include confusion, disorientation, and difficulty with language, reasoning, and problem-solving. Lewy body dementia (LBD) is a type of dementia characterized by the presence of abnormal protein deposits called Lewy bodies in the brain. These deposits disrupt the normal functioning of brain cells, leading to cognitive impairment, changes in behavior, and other symptoms.

    Cognitive impairment in LBD can manifest as difficulties with memory, reasoning, problem-solving, and other cognitive functions.

    Mild Cognitive Impairment Market Treatment Insights

    The Mild Cognitive Impairment Market has been segmented into medication and therapy. The medication segment dominated the market in 2022 and therapy is projected to be the fastest-growing during the forecast period, 2023–2032. Cognitive impairment can result from various underlying conditions such as Alzheimer's disease, vascular dementia, mild cognitive impairment, etc. Treatment options depend on the cause and severity of the impairment. Cognitive Stimulation Therapy (CST) is an evidence-based psychosocial intervention designed to improve cognitive function, quality of life, and well-being in people with cognitive impairment, particularly those with dementia.

    CST is typically delivered in a group format and involves a variety of activities and discussions aimed at stimulating cognitive abilities and social interaction. Cognitive Behavioral Therapy (CBT) has primarily been developed and utilized to treat various mental health conditions such as depression, anxiety disorders, and PTSD. However, there's been growing interest and some research in using CBT techniques to address cognitive impairment, particularly in populations like older adults or individuals with neurological conditions such as mild cognitive impairment (MCI) or dementia.

    Get more detailed insights about Mild Cognitive Impairment Market Research Report - Global Forecast till 2032

    Regional Insights

    By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America mild cognitive impairment market accounted for the largest market share of 42.60% in 2022 and is anticipated to reach approximately USD 01.31 billion by 2032 at a 4.97% CAGR during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 6.91% during the forecast period. The outlook for the North America mild cognitive impairment market remains promising, with sustained growth anticipated.

    Investments in healthcare infrastructure and a growing awareness of advanced medical solutions are expected to drive market expansion further. Both established players and emerging entrants are poised to capitalize on these opportunities, leveraging technological advancements to meet the rising demand for improved surgical outcomes.

    Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 3: MILD COGNITIVE IMPAIRMENT MARKET BY REGION 2023 & 2032 (USD Billion)

    MILD COGNITIVE IMPAIRMENT MARKET BY REGION 2022 & 2032

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe mild cognitive impairment market accounted for the second-largest market share due to technology advancements, increasing healthcare expenditure, and increasing burden of mild cognitive impairment. Furthermore, the Germany mild cognitive impairment market is attributed to hold the largest market share, and the UK mild cognitive impairment market is projected be the fastest growing market in the Europe region.

    The Asia-pacific mild cognitive impairment market is expected to be the fastest growing from 2024 to 2032 owing to high patient population, rising number of mild cognitive cases, and favorable regulatory policies. Moreover, key players working in the mild cognitive impairment market are actively expanding into this region, further driving the regional market growth. Moreover, China mild cognitive impairment market accounted to hold the largest market share, and the India mild cognitive impairment market is projected to be the fastest growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    The Mild Cognitive Impairment Market is distinguished by the presence of numerous regional and local players catering to mild cognitive impairment market products that are evolving at a rapid pace. Furthermore, the increasing burden of mild cognitive impairment across the globe and rising awareness associated with mild cognitive impairment in the healthcare industry is further driving the growth of Mild Cognitive Impairment Market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach.

    Eisai Co., Ltd. manufactures prescription drugs and medical equipment and primarily sells to sales agents and subsidiaries. They aim to provide services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia.

    In January 2023, Eisai Co., Ltd. (Japan) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD.

    Key Companies in the Mild Cognitive Impairment Market market include

    Industry Developments

      • January 2023, Biogen (US) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD developed in collaboration with Eisai Co., Ltd (Japan).

    Future Outlook

    Mild Cognitive Impairment Market Future Outlook

    The Global Mild Cognitive Impairment Market is projected to grow at a 5.95% CAGR from 2025 to 2035, driven by increasing awareness, advancements in diagnostics, and rising geriatric populations.

    New opportunities lie in:

    • Develop digital therapeutics tailored for cognitive enhancement.
    • Invest in AI-driven diagnostic tools for early detection.
    • Create partnerships with healthcare providers for integrated care solutions.

    By 2035, the market is expected to exhibit robust growth, reflecting heightened demand and innovation.

    Market Segmentation

    Outlook

    • Amnestic MCI
    • Non-Amnestic MCI

    Mild Cognitive Impairment Age Outlook

    • Child
    • Adult
    • Geriatric

    Mild Cognitive Impairment Regional Outlook

    • US
    • Canada

    Mild Cognitive Impairment Treatment Outlook

    • Cholinesterase Inhibitors
    • Benzodiazepines
    • Glutamate Inhibitors
    • Antihistamines
    • Mao Inhibitors
    • Proton Pump Inhibitors

    Mild Cognitive Impairment Indication Outlook

    • Lewy Body Dementia
    • Parkinson's Disease Dementia
    • Alzheimer’s Disease
    • Vascular Dementia
    • Others

     Mild Cognitive Impairment Disease Type Outlook

    • Amnestic MCI
    • Non-Amnestic MCI

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024 USD 2.05 Billion
    Market Size 2035 3.87
    Compound Annual Growth Rate (CAGR) 5.95% (2025 - 2035)
    Base Year 2024
    Forecast Period 2025 - 2035
    Historical Data 2019 to 2021
    Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered  Disease Type, Age, Indication, Treatment, and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled ·       Johnson & Johnson Services, Inc. (US) ·       Pfizer Inc. (US) ·       Novartis AG (Switzerland) ·       AbbVie Inc. (US) ·       Biogen (Switzerland) ·       Eisai Co., Ltd.  (JAPAN) ·       Aurobindo Pharma (India) ·       Sun Pharmaceutical Industries Ltd (India) ·      Teva Pharmaceutical Industries Ltd. (Israel) ·      Taj Pharmaceuticals Limited (India)  
    Key Market Opportunities ·       Technological advancements for early diagnosis of MCI
    Key Market Drivers ·       Increasing burden of mild cognitive impairment across the globe ·       Rising awareness associated with mild cognitive impairment.  
    Market Size 2025 2.17

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    How Big is the Mild Cognitive Impairment market?

    The global mild cognitive impairment market size is expected to reach USD 3.25 Billion at CAGR of 5.95% during the forecast period (2024 - 2032)

    Who are the key competitors in the market of Mild Cognitive Impairment?

    Pfizer Inc. (US), F. Hoffman La Roche Ltd (Switzerland), Novartis AG (Switzerland), Accord UK Ltd (UK), Dr. Reddy’s laboratories Ltd (India), Hikma Pharmaceuticals PLC (UK), Sun Pharmaceuticals ltd (India), Johnson & Johnson Services, Inc., (US), Teva Pharmaceutical Industries Ltd., (Israel), and Takeda Pharmaceutical Company Limited (US) are the leading players in the market of Mild Cognitive Impairment.

    Which region is predicted to have the largest market share of Mild Cognitive Impairment?

    North America holds the largest share in the global market of Mild Cognitive Impairment.

    What are the key factors driving the market of Mild Cognitive Impairment?

    Increasing geriatric population and Rising awareness about mild cognitive impairment are the key factors driving the market of Mild Cognitive Impairment.

    Which factors may act as market deterrents of Mild Cognitive Impairment?

    Unavailability of specific treatment may act as market deterrents of Mild Cognitive Impairment

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials